Code Securities: Banking on a Biotech Revival
When Chris Collins, former head of life sciences at WestLB Panmure, launched Code Securities in November 2003, he was taking a big gamble: biotech deals and IPOs are still at a low ebb, so is investor confidence. Collins is betting on a pick up, hoping that some of Europe's biotechs will see his experienced, dedicated team as a credible, more stable alternative to the bulge bracket banks, many of which were forced to abandon their smaller clients during the downturn.
You may also be interested in...
COVID-19 has triggered a dramatic shift toward virtual consultations and telemedicine, encouraged by more relaxed regulations and payer support.
As the global shut-down caused by the coronavirus pandemic continues, sponsors are rushing to adapt clinical trials that can move to partial or completely remote monitoring, allowing patients to remain in their homes but continue to participate in studies. And the outbreak may have another silver lining for the biopharma industry, a chance to rebuild its reputation.
Oncology and rare diseases dominate the industry pipeline, fuelled by science, regulatory tailwinds and high prices. But as the world grapples with coronavirus, and with heart disease still the top killer, can our systems fund treatments for more prevalent conditions?